Vabysmo (faricimab) launches — 2022
Roche's bispecific antibody, targeting both VEGF-A and Ang-2, won FDA approval for wet AMD and diabetic macular edema in January 2022. It competed with Eylea by offering dosing intervals up to every four months after loading, and became one of the fastest-growing ophthalmic drugs.
Eylea faced its first serious branded challenger on dosing convenience, prompting Regeneron to respond with a higher-dose version, Eylea HD.
Proved that dosing frequency is a decisive competitive lever in anti-VEGF therapy.
Kodiak's 54% six-month durability extends the same convenience playbook Vabysmo used to take market share.
